비원 메디슨즈(ONC) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

ONC

BeOne Medicines Ltd ADR

7월 27일 12:37 PM ET (한국 7/28 01:37)

$325.90

-0.87 ▼ -0.27%

비원 메디슨즈(ONC) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$33.3B

미드캡

P/E

72.7

고평가 구간

배당수익률

없음

52주 위치

55%

저점 +28% · 고점 -15%

애널리스트

적극 매수

Fundamental health

vs. Biotechnology 대형주

수익성

Top 48%

성장

Top 18%

밸류에이션

Top 38%

재무 안정

Top 48%

Index ⓘ	-	P/E ⓘ	72.72	EPS (ttm) ⓘ	4.48	Insider Own ⓘ	0.52%	Shs Outstand ⓘ	102.3M	Perf Week ⓘ	4.45%
Market Cap ⓘ	33.34B	Forward P/E ⓘ	33.18	EPS next Y ⓘ	44.04%	Insider Trans ⓘ	-56.98%	Shs Float ⓘ	101.8M	Perf Month ⓘ	17.6%
Enterprise Value ⓘ	30.56B	PEG ⓘ	0.46	EPS next Q ⓘ	1.63	Inst Own ⓘ	33.71%	Short Float ⓘ	0.78%	Perf Quarter ⓘ	8.7%
Income ⓘ	0.51B	P/S ⓘ	5.79	EPS this Y ⓘ	159.24%	Inst Trans ⓘ	-0.49%	Short Ratio ⓘ	2.63	Perf Half Y ⓘ	-3.81%
Sales ⓘ	5.76B	P/B ⓘ	7.61	EPS next 5Y ⓘ	72.32%	ROA ⓘ	7.15%	Short Interest ⓘ	0.79M	Perf YTD ⓘ	7.27%
Book/sh ⓘ	42.84	P/C ⓘ	6.9	EPS past 3/5Y ⓘ	-	ROE ⓘ	12.46%	52W High ⓘ	-15.4% ($385.22)	Perf Year ⓘ	9.93%
Cash/sh ⓘ	47.24	P/FCF ⓘ	29.83	Sales past 3/5Y ⓘ	55.88% 76.88%	ROIC ⓘ	7.79%	52W Low ⓘ	28.33% ($253.95)	Perf 3Y ⓘ	66.92%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	36.45	EPS Y/Y TTM ⓘ	225.57%	Gross Margin ⓘ	86.15%	Volatility(W/M) ⓘ	3.14% 2.72%	Perf 5Y ⓘ	2.83%
Dividend TTM ⓘ	-	EV/Sales ⓘ	5.31	Sales Y/Y TTM ⓘ	37.7%	Oper. Margin ⓘ	11.95%	ATR (14) ⓘ	9.43	Perf 10Y ⓘ	1093.77%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	3.27	EPS Q/Q ⓘ	17028.7%	Profit Margin ⓘ	8.94%	RSI (14) ⓘ	69.53	Recom ⓘ	1.19
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	3.64	Sales Q/Q ⓘ	35.67%	SMA20 ⓘ	6.54% ($305.89)	Beta ⓘ	0.48	Target Price ⓘ	$417.42
Payout ⓘ	-	Debt/Eq ⓘ	0.43	Earnings ⓘ	2026/8/5	SMA50 ⓘ	11.55% ($292.16)	Rel Volume ⓘ	1.15	Prev Close ⓘ	$326.77
Employees ⓘ	12000	LT Debt/Eq ⓘ	0.39	EPS/Sales Surpr. ⓘ	82.22% 5.35%	SMA200 ⓘ	3.69% ($314.3)	Avg Volume(3M) ⓘ	0.30M	Price ⓘ	$325.9
IPO ⓘ	2016/2/3	Option/Short ⓘ	Yes/Yes			Trades ⓘ	10404	Volume ⓘ	346,475	Change ⓘ	-0.27%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $1.5B (YoY +35%) · 순이익 $227M (YoY +17802%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 BeOne Medicines Ltd ADR (ONC) Investment Analysis

What kind of company is BeOne Medicines Ltd ADR?

비원 메디슨즈(ONC) 초고성장주

Healthcare · Biotechnology

Top 426 by Market Cap — Large-Cap

💊 This is a global biotech company focused on anti-cancer therapeutics. Founded in 2010 and headquartered in Basel, Switzerland, the company, which changed its name from BeiGene and trades under the ticker ONC, is a large-cap biotech holding a pipeline of BTK inhibitors and other candidates for hematologic cancers and solid tumors, making it a key name riding the wave of expansion in the global oncology drug market.

Learn more about BeOne Medicines Ltd ADR →

Market Cap

$33.3B

Approx. KRW 45.7 trillion

⚖️ 11% of Samsung Electronics

Market Cap Rank426

Employees12,000people

IPO2016/02/03

Current Price$325.90 ≈ 446,483원

NASD · Switzerland

Key Events

⏰ Upcoming events

🔔 Earnings release D-9

8월 5일 (수) · 장 시작 전

예상 EPS $1.63

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 6일 (수) · 장 시작 전 EPS +82.2% 매출 +5.3%

🔔 Earnings release 2026년 2월 26일 (목) · 장 시작 전 EPS -51.8% 매출 +2.2%

Is it profitable?

Financial health solid

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

11.9%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 14.7% · Bottom 49%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

8.9%

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 8.6% · Top 50%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

86.2%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 86.4% · Bottom 49%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

12.5%

✓ 양호

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 11.9% · Top 49%

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

7.2%

✓ 양호

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 5.1% · Top 40%

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

7.8%

✓ 양호

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 7.4% · Top 49%

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.43

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

3.64

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

3.27

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$417.42

현재가 대비 +28.1%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

33.18배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

0.46

저평가

💡 PEG < 1 — 성장 대비 저렴

내년 EPS 예상 성장률

+44.0%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+72.3%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

+44.0%

평균 서프라이즈

2026.05.06

상회

실적 $1.96 · 예상 $0.81 +143.3%

2026.02.26

하회

실적 $0.58 · 예상 $1.30 -55.3%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth

Above the industry average, both historically and going forward

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+159.2%

우수

My positionTop 25%

Low range Average High range

초고성장주 대형주 Median 47.1% · Top 13%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+44.0%

양호

My positionMid-range

Low range Average High range

초고성장주 대형주 Median 32.1% · Top 31%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+72.3%

우수

My positionTop 25%

Low range Average High range

초고성장주 대형주 Median 36.4% · Top 10%

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+76.9%

우수

My positionTop 5%

Low range Average High range

초고성장주 대형주 Median 28.9% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+35.7%

양호

My positionMid-range

Low range Average High range

초고성장주 대형주 Median 25.3% · Top 36%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -65%p below the market

ONC +2.8% · S&P 500 +68.0%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-65.1%p

Significantly behind the market

vs Health Care (XLV)

-20.8%p

behind the sector average

1-year basis

vs S&P 500

-6.5%p

slightly behind the market

vs Health Care (XLV)

-9.8%p

slightly behind the sector average

Rank among peers

5-year return Bottom 23% Based on 24 peers

1-year return Lower-Mid (lower 26%) Based on 24 peers

Current position within 52-week range

Low (-28.3%p) High (-15.4%p)

Current price is 28.3% above the 52-week low and 15.4% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-29.8%

Annualized volatility

36.2%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-24

Uptrend zone

Current price $325.90 above the midline ($305.90). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-07-24

Bullish momentum holding

MACD 9.957 > Signal 7.896 in positive zone + Hist positive (+2.061). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-24

Bullish zone

RSI 69.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 84.4.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Sales, Pricey on Vs. Earnings, In line with peers on Vs. Assets·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Mid-range

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

72.72x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Biotechnology median 15.34x · Bottom 2% — expensive within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

33.18x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 대형주 median 22.38x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

7.61x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 대형주 median 7.26x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

5.79x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 대형주 median 9.45x · Top 25% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

36.45x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 22.58x · Around the industry average

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

29.83x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 18.43x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$417.42 vs. current price +28.1%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership flow shows some pressure

Insider net selling -57.0% · Institutional modest net selling -0.5% · Short interest light 0.8% · Short interest fell -0.6%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-57.0%

Insiders large net selling

🏦 Institutions (funds & investors)

-0.5%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 33.7%

Moderate institutional participation

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 0.5%

Low, common among large-caps

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 65.8%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.8%

Low — limited short-side pressure

Healthcare 대형주 Median 3.6%

Past 90 days 📉 -0.6%p decrease

Short interest days to cover

2.6 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 102.3M주

Float (tradable shares) 101.8M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ONC

ETFs with the highest weightings · 10 total shown

KURE

KraneShares MSCI All China Health Care Index ETF

First Trust NYSE Arca Biotechnology Index Fund

3.12%

$2.8B

AGNG

Global X Aging Population ETF

2.05%

$86M

IBB

iShares Biotechnology ETF

1.93%

$9.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
ONC This Stock	$33.3B	72.7 ▼	7.6 ▼	12.46% ▲	-	-0.3%
LLY	$1.13T	43.0 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.9%
JNJ	$634.1B	30.5 ▼	7.5 ▼	25.74% ▲	2.04% ▲	+1.6%
ABBV	$458.2B	127.9 ▼	-	15221.82% ▲	2.65% ▲	+0.9%
UNH	$382.1B	27.1 ▼	3.9 ▼	12.49% ▲	2.15% ▲	-0.7%
MRK	$323.7B	36.9 ▼	7.1 ▼	18.97% ▲	2.49% ▲	+0.5%
Sector Avg	-	25.8	2.7	-48.83%	1.25%	-

FAQ

What kind of company is 비원 메디슨즈(ONC)?

비원 메디슨즈(ONC) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ONC?

The market cap of ONC is approximately $33.3B, ranking 426 within its sector.

What is the P/E ratio of ONC?

ONC has a P/E ratio of approximately 72.7x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for ONC?

ONC has recorded a 52-week high of $385.22 and a low of $253.95.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.